Compare EVTL & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | CGEN |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.6M | 191.1M |
| IPO Year | 2021 | 2001 |
| Metric | EVTL | CGEN |
|---|---|---|
| Price | $0.67 | $2.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $12.70 | $5.00 |
| AVG Volume (30 Days) | ★ 9.7M | 345.5K |
| Earning Date | 03-24-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.67 | $1.30 |
| 52 Week High | $7.35 | $3.24 |
| Indicator | EVTL | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 25.17 | 60.10 |
| Support Level | N/A | $2.54 |
| Resistance Level | $1.42 | $3.05 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 1.59 | 63.78 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.